Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


2 Am J Hematol
1 Ann Hematol
3 Blood
1 Bone Marrow Transplant
6 Br J Haematol
1 Cancer
1 Gene
1 Genes Chromosomes Cancer
2 J Clin Oncol
1 J Natl Cancer Inst
2 J Pediatr Hematol Oncol
1 J Virol
4 Leuk Lymphoma
4 Leuk Res
2 Leukemia
2 PLoS One
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Hematol

  1. TEFFERI A, Gangat N, Al-Kali A, Alkhateeb H, et al
    A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
    Am J Hematol. 2022 Jun 15. doi: 10.1002/ajh.26630.
    PubMed         Abstract available

  2. BADAR T, Atallah E, Shallis RM, Goldberg AD, et al
    Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival.
    Am J Hematol. 2022;97:E232-E235.

    Ann Hematol

  3. YANG X, Zhang R, Zhang Z
    The rare IRF2BP2-RARA fusion in acute promyelocytic leukemia.
    Ann Hematol. 2022 Jun 15. pii: 10.1007/s00277-022-04874.


  4. CHEMINANT M, Lhermitte L, Bruneau J, Sicard H, et al
    KIR3DL2 contributes to the typing of acute-type adult T-cell leukemia and is a potential therapeutic target.
    Blood. 2022 Jun 10. pii: 485527. doi: 10.1182/blood.2022016765.
    PubMed         Abstract available

  5. ALVAREZ S, da Silva Almeida AC, Albero R, Biswas M, et al
    Functional mapping of PHF6 complexes in chromatin remodeling, replication dynamics, and DNA repair.
    Blood. 2022;139:3418-3429.
    PubMed         Abstract available

  6. PERL AE, Larson RA, Podoltsev NA, Strickland S, et al
    Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
    Blood. 2022;139:3366-3375.
    PubMed         Abstract available

    Bone Marrow Transplant

  7. LAZZARI L, Balaguer-Rosello A, Montoro J, Greco R, et al
    Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
    Bone Marrow Transplant. 2022 Jun 9. pii: 10.1038/s41409-022-01725.
    PubMed         Abstract available

    Br J Haematol

  8. WHITE T, Kaspers G, Abrahamsson J, Arad-Cohen N, et al
    Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: A retrospective study within the NOPHO-DB SHIP consortium.
    Br J Haematol. 2022;197:755-765.
    PubMed         Abstract available

  9. MORI A, Onozawa M, Tsukamoto S, Ishio T, et al
    Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
    Br J Haematol. 2022;197:691-696.
    PubMed         Abstract available

  10. TARIQ H, Barnea Slonim L, Coty Fattal Z, Alikhan MB, et al
    Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype.
    Br J Haematol. 2022;197:736-744.
    PubMed         Abstract available

  11. LYNGGAARD LS, Vaitkeviciene G, Langenskiold C, Lehmann AK, et al
    Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:745-754.
    PubMed         Abstract available

  12. WANG M, Lin H, Chu X, Wang Z, et al
    Identification of a recurrent fusion NUP98-RARG in acute myeloid leukaemia resembling acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:e73-e78.

  13. MERLI P
    Treating second-relapsed/refractory first-relapsed childhood acute myeloid leukaemia: Successful salvage rather than palliation?
    Br J Haematol. 2022;197:651-652.
    PubMed         Abstract available


  14. ALVAREZ-LARRAN A, Garrote M, Ferrer-Marin F, Perez-Encinas M, et al
    Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
    Cancer. 2022;128:2441-2448.
    PubMed         Abstract available


  15. DHIFLAOUI A, Mahjoub S, Chayeb V, Achour B, et al
    miR-146a, miR-196a2, miR-499, and miR-149 linked with susceptibility to acute lymphoblastic leukemia: A case-control study in Tunisia.
    Gene. 2022;834:146648.
    PubMed         Abstract available

    Genes Chromosomes Cancer

  16. RUETHER C, Wuensch C, Randau G, Michgehl U, et al
    Design of a targeted next-generation DNA sequencing panel for pediatric T-cell lymphoblastic lymphoma to unravel biology and optimize treatment.
    Genes Chromosomes Cancer. 2022;61:459-470.
    PubMed         Abstract available

    J Clin Oncol

  17. HANTEL A, Kohlschmidt J, Eisfeld AK, Stock W, et al
    Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention.
    J Clin Oncol. 2022 Jun 13:JCO2200307. doi: 10.1200/JCO.22.00307.
    PubMed         Abstract available

  18. KADIA TM, Reville PK, Wang X, Rausch CR, et al
    Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
    J Clin Oncol. 2022 Jun 15:JCO2102823. doi: 10.1200/JCO.21.02823.
    PubMed         Abstract available

    J Natl Cancer Inst

  19. KEATING NL, Brooks GA, Landrum MB, Liu PH, et al
    The Oncology Care Model and Adherence to Oral Cancer Drugs: A Difference-in-Differences Analysis.
    J Natl Cancer Inst. 2022;114:871-877.
    PubMed         Abstract available

    J Pediatr Hematol Oncol

  20. HANDATTU K, Sharma LK, Vijayasekharan K, Bhat K V, et al
    Drug Induced Diabetes Mellitus (DIDM) in Pediatric Acute Lymphoblastic Leukemia: Approach to diagnosis and management.
    J Pediatr Hematol Oncol. 2022 Jun 7. pii: 00043426-990000000-00044.
    PubMed         Abstract available

  21. SEZGIN EVIM M, Yoruk G, Guler S, Parlak A, et al
    The Evaluation of Central Venous Catheter-related Complications in Pediatric Acute Leukemia Patients: Single Center Experience.
    J Pediatr Hematol Oncol. 2022 Jun 7. pii: 00043426-990000000-00042.
    PubMed         Abstract available

    J Virol

  22. LI Y, He M, Gong R, Wang Z, et al
    Forkhead O Transcription Factor 4 Restricts HBV Covalently Closed Circular DNA Transcription and HBV Replication through Genetic Downregulation of Hepatocyte Nuclear Factor 4 Alpha and Epigenetic Suppression of Covalently Closed Circular DNA via Inter
    J Virol. 2022 Jun 13:e0054622. doi: 10.1128/jvi.00546.
    PubMed         Abstract available

    Leuk Lymphoma

  23. MOLICA S, Allsup DJ, Polliack A
    Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Jun 15:1-3. doi: 10.1080/10428194.2022.2087072.

  24. YU G, Lu W, Chen X, Li Y, et al
    Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission.
    Leuk Lymphoma. 2022 Jun 11:1-12. doi: 10.1080/10428194.2022.2086243.
    PubMed         Abstract available

  25. LYU X, Li T, Zhu D, Cheng Y, et al
    Whole-genome sequencing as an alternative to analyze copy number abnormalities in acute myeloid leukemia and myelodysplastic syndrome.
    Leuk Lymphoma. 2022 Jun 11:1-10. doi: 10.1080/10428194.2022.2080821.
    PubMed         Abstract available

  26. SABURI M, Sakata M, Takata H, Miyazaki Y, et al
    Poor clinical outcome of elderly patients with primary plasma cell leukemia treated with novel agents: real-world experience.
    Leuk Lymphoma. 2022 Jun 10:1-5. doi: 10.1080/10428194.2022.2086250.

    Leuk Res

  27. LIU J, Qin W, Wang B, Wang Z, et al
    PTPN11 mutations in adult acute myeloid leukaemia: Prevalence and clinical implications in the context of NPM1 mutation.
    Leuk Res. 2022;118:106859.
    PubMed         Abstract available

  28. CHAUVET P, Nibourel O, Berthon C, Goursaud L, et al
    Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.
    Leuk Res. 2022;118:106871.
    PubMed         Abstract available

  29. ZHAO D, Zarif M, Eladl E, Capo-Chichi JM, et al
    NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.
    Leuk Res. 2022;118:106869.
    PubMed         Abstract available

  30. KIM K, Bazinet A, Loghavi S, Konopleva M, et al
    Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine.
    Leuk Res. 2022;119:106884.


  31. BUENO-COSTA A, Pineyro D, Garcia-Prieto CA, Ortiz-Barahona V, et al
    Remodeling of the m(6)A RNA landscape in the conversion of acute lymphoblastic leukemia cells to macrophages.
    Leukemia. 2022 Jun 9. pii: 10.1038/s41375-022-01621.

  32. WEI Y, Kanagal-Shamanna R, Zheng H, Bao N, et al
    Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.
    Leukemia. 2022 Jun 14. pii: 10.1038/s41375-022-01605.
    PubMed         Abstract available

    PLoS One

  33. SIAMAKPOUR-REIHANI S, Cao F, Lyu J, Ren Y, et al
    Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia.
    PLoS One. 2022;17:e0268963.
    PubMed         Abstract available

  34. GARNIASIH D, Susanah S, Sribudiani Y, Hilmanto D, et al
    The incidence and mortality of childhood acute lymphoblastic leukemia in Indonesia: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0269706.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  35. DONG H, Ham JD, Hu G, Xie G, et al
    Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia.
    Proc Natl Acad Sci U S A. 2022;119:e2122379119.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.